HRP20230834T1 - Postupci za proizvodnju personaliziranih krvnih žila - Google Patents
Postupci za proizvodnju personaliziranih krvnih žila Download PDFInfo
- Publication number
- HRP20230834T1 HRP20230834T1 HRP20230834TT HRP20230834T HRP20230834T1 HR P20230834 T1 HRP20230834 T1 HR P20230834T1 HR P20230834T T HRP20230834T T HR P20230834TT HR P20230834 T HRP20230834 T HR P20230834T HR P20230834 T1 HRP20230834 T1 HR P20230834T1
- Authority
- HR
- Croatia
- Prior art keywords
- whole blood
- cell
- blood sample
- fgf
- concentration
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 22
- 210000004204 blood vessel Anatomy 0.000 title claims 5
- 210000004369 blood Anatomy 0.000 claims 18
- 239000008280 blood Substances 0.000 claims 18
- 239000000725 suspension Substances 0.000 claims 14
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 6
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims 4
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 4
- 239000003146 anticoagulant agent Substances 0.000 claims 4
- 229940126864 fibroblast growth factor Drugs 0.000 claims 4
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims 4
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 3
- 229920002307 Dextran Polymers 0.000 claims 3
- 108090000368 Fibroblast growth factor 8 Proteins 0.000 claims 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 3
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims 3
- 102000013275 Somatomedins Human genes 0.000 claims 3
- 229960001138 acetylsalicylic acid Drugs 0.000 claims 3
- 230000002785 anti-thrombosis Effects 0.000 claims 3
- 229960005070 ascorbic acid Drugs 0.000 claims 3
- 235000010323 ascorbic acid Nutrition 0.000 claims 3
- 239000011668 ascorbic acid Substances 0.000 claims 3
- 230000001413 cellular effect Effects 0.000 claims 3
- 230000007613 environmental effect Effects 0.000 claims 3
- 239000003102 growth factor Substances 0.000 claims 3
- 229960002897 heparin Drugs 0.000 claims 3
- 229920000669 heparin Polymers 0.000 claims 3
- 235000015097 nutrients Nutrition 0.000 claims 3
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims 2
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims 2
- 108010055166 Chemokine CCL5 Proteins 0.000 claims 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 2
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 claims 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 claims 2
- 108010063738 Interleukins Proteins 0.000 claims 2
- 102000015696 Interleukins Human genes 0.000 claims 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 claims 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 claims 2
- 108010009583 Transforming Growth Factors Proteins 0.000 claims 2
- 102000009618 Transforming Growth Factors Human genes 0.000 claims 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 2
- 230000023555 blood coagulation Effects 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000012544 monitoring process Methods 0.000 claims 2
- 210000000440 neutrophil Anatomy 0.000 claims 2
- 102000005162 pleiotrophin Human genes 0.000 claims 2
- 102000003390 tumor necrosis factor Human genes 0.000 claims 2
- 102100032367 C-C motif chemokine 5 Human genes 0.000 claims 1
- 102000001327 Chemokine CCL5 Human genes 0.000 claims 1
- 125000002353 D-glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims 1
- 108090000378 Fibroblast growth factor 3 Proteins 0.000 claims 1
- 102100028043 Fibroblast growth factor 3 Human genes 0.000 claims 1
- 108090000381 Fibroblast growth factor 4 Proteins 0.000 claims 1
- 102100028072 Fibroblast growth factor 4 Human genes 0.000 claims 1
- 108090000380 Fibroblast growth factor 5 Proteins 0.000 claims 1
- 102100028073 Fibroblast growth factor 5 Human genes 0.000 claims 1
- 108090000382 Fibroblast growth factor 6 Proteins 0.000 claims 1
- 102100028075 Fibroblast growth factor 6 Human genes 0.000 claims 1
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 claims 1
- 102100028071 Fibroblast growth factor 7 Human genes 0.000 claims 1
- 102100037680 Fibroblast growth factor 8 Human genes 0.000 claims 1
- 108090000367 Fibroblast growth factor 9 Proteins 0.000 claims 1
- 102100037665 Fibroblast growth factor 9 Human genes 0.000 claims 1
- 102000018710 Heparin-binding EGF-like Growth Factor Human genes 0.000 claims 1
- 101800001649 Heparin-binding EGF-like growth factor Proteins 0.000 claims 1
- 101001052035 Homo sapiens Fibroblast growth factor 2 Proteins 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 108090000978 Interleukin-4 Proteins 0.000 claims 1
- 108090001007 Interleukin-8 Proteins 0.000 claims 1
- 102000004890 Interleukin-8 Human genes 0.000 claims 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 1
- 229960004676 antithrombotic agent Drugs 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 229940119744 dextran 40 Drugs 0.000 claims 1
- 238000002513 implantation Methods 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- -1 neutrophil (NT)-6 Proteins 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 230000010412 perfusion Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
- A61L27/3616—Blood, e.g. platelet-rich plasma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/507—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials for artificial blood vessels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
- A61F2/06—Blood vessels
- A61F2/062—Apparatus for the production of blood vessels made from natural tissue or with layers of living cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
- A61L27/3625—Vascular tissue, e.g. heart valves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
- A61L27/3687—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
- A61L27/3882—Hollow organs, e.g. bladder, esophagus, urether, uterus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/0005—Use of materials characterised by their function or physical properties
- A61L33/0011—Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M21/00—Bioreactors or fermenters specially adapted for specific uses
- C12M21/08—Bioreactors or fermenters specially adapted for specific uses for producing artificial tissue or for ex-vivo cultivation of tissue
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M25/00—Means for supporting, enclosing or fixing the microorganisms, e.g. immunocoatings
- C12M25/14—Scaffolds; Matrices
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M29/00—Means for introduction, extraction or recirculation of materials, e.g. pumps
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M41/00—Means for regulation, monitoring, measurement or control, e.g. flow regulation
- C12M41/26—Means for regulation, monitoring, measurement or control, e.g. flow regulation of pH
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M41/00—Means for regulation, monitoring, measurement or control, e.g. flow regulation
- C12M41/30—Means for regulation, monitoring, measurement or control, e.g. flow regulation of concentration
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M41/00—Means for regulation, monitoring, measurement or control, e.g. flow regulation
- C12M41/30—Means for regulation, monitoring, measurement or control, e.g. flow regulation of concentration
- C12M41/34—Means for regulation, monitoring, measurement or control, e.g. flow regulation of concentration of gas
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2240/00—Manufacturing or designing of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2240/001—Designing or manufacturing processes
- A61F2240/002—Designing or making customized prostheses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/21—Acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/23—Carbohydrates
- A61L2300/232—Monosaccharides, disaccharides, polysaccharides, lipopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/23—Carbohydrates
- A61L2300/236—Glycosaminoglycans, e.g. heparin, hyaluronic acid, chondroitin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
- A61L2300/414—Growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/42—Anti-thrombotic agents, anticoagulants, anti-platelet agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/40—Preparation and treatment of biological tissue for implantation, e.g. decellularisation, cross-linking
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Sustainable Development (AREA)
- General Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Botany (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Materials Engineering (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
Claims (20)
1. Postupak za proizvodnju personalizirane krvne žile, naznačen time, da obuhvaća stavljanje u doticaj površine bezstaničnog cjevastog postolja sa suspenzijom koja sadrži uzorak pune krvi od pojedinca kojemu je potrebna personalizirana krvna žila, pri čemu se uzorak pune krvi razrjeđuje u fiziološkoj otopini i pritom se stavljanje u doticaj izvršava u vremenu od 3 do 14 dana.
2. Postupak prema patentnom zahtjevu 1, naznačen time, da stanična populacija u uzorku pune krvi nastanjuje bezstanično cjevasto postolje.
3. Postupak prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da uzorak pune krvi sadrži jedan ili više nestaničnih faktora, pri čemu jedan ili više nestaničnih faktora pune krvi nastanjuje postolje, i time, da nestanični faktori potiču celularizaciju bezstaničnog cjevastog postolja i kompatibilnost domaćina krvne žile nakon usađivanja.
4. Postupak prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da suspenzija koja sadrži uzorak pune krvi nadalje sadrži antitrombotički faktor.
5. Postupak prema patentnom zahtjevu 4, naznačen time, da antitrombotički faktor sadrži sredstvo protiv zgrušavanja krvi.
6. Postupak prema patentnom zahtjevu 5, naznačen time, da sredstvo protiv zgrušavanja krvi sadrži heparin ili dekstran.
7. Postupak prema patentnom zahtjevu 6, naznačen time, da se heparin nalazi u suspenziji koja sadrži uzorak pune krvi na početku njezinog stavljanja u doticaj s površinom bezstaničnog cjevastog postolja, u koncentraciji od 0,5 IU/mL +/- 10% do 150 IU/mL +/- 10%, opcionalno pritom heparin se nalazi u nerazrijeđenom uzorku pune krvi ili u suspenziji koja sadrži uzorak pune krvi na početku njezinog stavljanja u doticaj s površinom bezstaničnog cjevastog postolja, u koncentraciji od 6,7 IU/mL +/- 10%.
8. Postupak prema patentnom zahtjevu 6, naznačen time, da dekstran je dekstran-40.
9. Postupak prema patentnom zahtjevu 6, naznačen time, da se dekstran nalazi u suspenziji koja sadrži uzorak pune krvi na početku njezinog stavljanja u doticaj s površinom bezstaničnog cjevastog postolja, u koncentraciji od 1 g/L +/- 10% do 55 g/L +/- 10%.
10. Postupak prema patentnom zahtjevu 4, naznačen time, da antitrombotičko sredstvo sadrži askorbinsku kiselinu.
11. Postupak prema patentnom zahtjevu 10, naznačen time, da se askorbinska kiselina nalazi u suspenziji koja sadrži uzorak pune krvi na početku njezinog stavljanja u doticaj s površinom bezstaničnog cjevastog postolja, u koncentraciji od 0,2 μg/mL +/- 10% do 200 μg/mL +/- 10%, opcionalno pritom se koncentracija askorbinske kiseline nalazi u suspenziji koja sadrži uzorak pune krvi na početku njezinog stavljanja u doticaj s površinom bezstaničnog cjevastog postolja, u koncentraciji od 5 μg/mL +/- 10%.
12. Postupak prema patentnom zahtjevu 4, naznačen time, da antitrombotički faktor sadrži acetilsalicilnu kiselinu.
13. Postupak prema patentnom zahtjevu 12, naznačen time, da se acetilsalicilna kiselina nalazi u suspenziji koja sadrži uzorak pune krvi na početku njezinog stavljanja u doticaj s površinom bezstaničnog cjevastog postolja, u koncentraciji od 0,2 μg/mL +/- 10% do 200 μg/mL +/- 10%, opcionalno pritom se acetilsalicilna kiselina nalazi u suspenziji koja sadrži uzorak pune krvi na početku njezinog stavljanja u doticaj s površinom bezstaničnog cjevastog postolja, u koncentraciji od 5 μg/mL +/- 10%.
14. Postupak prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da suspenzija koja sadrži uzorak pune krvi nadalje sadrži jednako ili više od prosječne fiziološke razine populacije faktora rasta odabranog iz skupine koju čine: stimulacijski faktor kolonije granulocita makrofaga (GM-CSF), interleukin (IL)-3, IL-4, neutrofin (NT)-6, pleiotrofin (HB-GAM), midkin (MK), inducirajući protein-10 interferona (IP-10), faktor krvnih pločica (PF)-4, monocitni kemotaktični protein-1 (MCP-1), RANTES (CCL-5, kemokin (C-C-motiv) ligand 5), IL-8, IGF, faktor rasta fibroblasta (FGF)-1, FGF-2, FGF-3, FGF-4, FGF-5, FGF-6, FGF-7, FGF-8, FGF-9, transformacijski faktor rasta (TGF)-β, VEGF, trombocitni faktor rasta (PDGF)-A, PDGF-B, HB-EGF, faktor rasta hepatocita (HGF), faktor nekroze tumora (TNF)-α, faktor rasta nalik na inzulin (IGF)-1, i bilo koja njihova kombinacija ili bilo koje njihove kombinacije, poželjno gdje faktor rasta je faktor rasta fibroblasta (FGF)-2, opcionalno pritom gdje FGF-2 jest ljudski FGF-2.
15. Postupak prema patentnom zahtjevu 1, naznačen time, da je stavljanje u doticaj u vremenskom periodu od 3 do 9 dana, i opcionalno time, da je stavljanje u doticaj u vremenskom periodu od 4 do 9 dana.
16. Postupak prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da se uzorak pune krvi razrjeđuje u fiziološkoj otopini od najmanje 15%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 110%, 120%, 130%, 140%, 150%, 160%, 170%, 180%, 190%, ili 200%, poželjno s time, da se uzorak pune krvi razrjeđuje 1:1.
17. Postupak prema patentnom zahtjevu 14, naznačen time, da se faktor rasta nadopunjava kao izolirana, pročišćena, i/ili sintetička molekula.
18. Postupak prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da postupak nadalje obuhvaća nadziranje koncentracije nutrijenta u suspenziji, pri čemu nutrijent je D-glukoza, dok se koncentracija D-glukoze neprekidno ili regularno podešava u svrhu održavanja koncentracije D-glukoze na 3 mmol/L +/- 10% do 11 mmol/L +/- 10%, poželjno pritom se koncentracija D-glukoze održava na 5 mmol/L +/- 10% do 8 mmol/L +/- 10%.
19. Postupak prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da se neprekidno vrši perfuzija bezstaničnog cjevastog postolja suspenzijom, pri čemu se opcionalno vrši perfuzija bezstaničnog cjevastog postolja brzinom od 0,1 mL +/- 10% do 50 mL +/- 10% u minuti, dok se opcionalno vrši perfuzija bezstaničnog cjevastog postolja brzinom od 2 mL +/- 10% u minuti, gdje se opcionalno vrši perfuzija postolja sa zatvorenom recirkulacijom suspenzije, te, opcionalno, time, da neprekidno stavljanje u doticaj jest perfuzija koja se provodi uporabom bioreaktora.
20. Postupak prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da se bezstanično cjevasto postolje stavlja u doticaj sa suspenzijom koja sadrži uzorak pune krvi, i postupak nadalje obuhvaća nadziranje čitavog niza okolišnih parametara i/ili koncentracije nutrijenta za vrijeme proizvodnje personalizirane krvne žile, s time, da nadalje obuhvaća prilagođavanje čitavog niza okolišnih parametara, dok čitav niz okolišnih parametara uključuje temperaturu, pH vrijednost, kisik, i/ili CO2.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862714200P | 2018-08-03 | 2018-08-03 | |
| PCT/IB2019/056621 WO2020026212A2 (en) | 2018-08-03 | 2019-08-02 | Methods of preparing personalized blood vessels |
| EP19779967.9A EP3830243B1 (en) | 2018-08-03 | 2019-08-02 | Methods of preparing personalized blood vessels |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20230834T1 true HRP20230834T1 (hr) | 2023-11-10 |
Family
ID=68104680
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20230834TT HRP20230834T1 (hr) | 2018-08-03 | 2019-08-02 | Postupci za proizvodnju personaliziranih krvnih žila |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US11471567B2 (hr) |
| EP (2) | EP4194541B1 (hr) |
| JP (2) | JP7208393B2 (hr) |
| KR (1) | KR102530336B1 (hr) |
| CN (1) | CN112805364A (hr) |
| AU (1) | AU2019315049B2 (hr) |
| BR (1) | BR112021001541B1 (hr) |
| CA (1) | CA3107918A1 (hr) |
| DK (1) | DK3830243T3 (hr) |
| ES (1) | ES2953744T3 (hr) |
| FI (1) | FI3830243T3 (hr) |
| HR (1) | HRP20230834T1 (hr) |
| HU (1) | HUE062715T2 (hr) |
| LT (1) | LT3830243T (hr) |
| MX (1) | MX2021001184A (hr) |
| PL (1) | PL3830243T3 (hr) |
| PT (1) | PT3830243T (hr) |
| RS (1) | RS64381B1 (hr) |
| SG (2) | SG11202101121YA (hr) |
| SI (1) | SI3830243T1 (hr) |
| WO (1) | WO2020026212A2 (hr) |
| ZA (1) | ZA202100888B (hr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113855859A (zh) * | 2021-05-28 | 2021-12-31 | 首都医科大学宣武医院 | 一种由脱细胞血管基质构建的可促进快速内皮化的小口径组织工程血管 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02274244A (ja) * | 1989-04-14 | 1990-11-08 | Yasunori Morohoshi | 人工血管およびその製造法 |
| US6376244B1 (en) | 1999-12-29 | 2002-04-23 | Children's Medical Center Corporation | Methods and compositions for organ decellularization |
| ATE390152T1 (de) * | 2000-04-28 | 2008-04-15 | Baylor College Medicine | Dezellularisierte gefässprothesen |
| WO2002035929A1 (en) | 2000-11-03 | 2002-05-10 | Vitrolife Ab | Evaluation and preservation solution |
| KR20070106696A (ko) * | 2004-12-24 | 2007-11-05 | 셀스셀 피티와이 엘티디 | 이식가능한 바이오물질 및 그 제조 방법 |
| WO2011002926A2 (en) * | 2009-07-01 | 2011-01-06 | The General Hospital Corporation | Isolated adult cells, artificial organs,rehabilitated organs, research rools, organ encasements, organ perfusion systems, and methods for preparing and utilizing the same |
| PL2782995T3 (pl) * | 2012-03-16 | 2017-05-31 | Novahep Ab | Biomodyfikowane alogeniczne naczynie krwionośne |
| RU2646506C1 (ru) | 2014-02-12 | 2018-03-05 | Торэй Индастриз, Инк. | Искусственный кровеносный сосуд |
| JP2016524954A (ja) | 2014-05-27 | 2016-08-22 | ノーバヘップ アーベー | 生物工学で作製された同種異系弁 |
| CN107106727B (zh) | 2014-10-31 | 2021-04-02 | 富士胶片株式会社 | 管状结构物、用于制造管状结构物的装置及管状结构物的制造方法 |
| KR102571649B1 (ko) * | 2014-12-19 | 2023-08-25 | 앤지오크린 바이오사이언스 인코포레이티드 | 조작된 내피 세포를 포함하는 생체적합성 임플란트 |
| CA3027505A1 (en) * | 2016-06-15 | 2017-12-21 | The General Hospital Corporation | Metabolic labeling and molecular enhancement of biological materials using bioorthogonal reactions |
-
2019
- 2019-08-02 SG SG11202101121YA patent/SG11202101121YA/en unknown
- 2019-08-02 PT PT197799679T patent/PT3830243T/pt unknown
- 2019-08-02 ES ES19779967T patent/ES2953744T3/es active Active
- 2019-08-02 LT LTEPPCT/IB2019/056621T patent/LT3830243T/lt unknown
- 2019-08-02 SI SI201930612T patent/SI3830243T1/sl unknown
- 2019-08-02 EP EP23153503.0A patent/EP4194541B1/en active Active
- 2019-08-02 DK DK19779967.9T patent/DK3830243T3/da active
- 2019-08-02 MX MX2021001184A patent/MX2021001184A/es unknown
- 2019-08-02 BR BR112021001541-8A patent/BR112021001541B1/pt active IP Right Grant
- 2019-08-02 CA CA3107918A patent/CA3107918A1/en active Pending
- 2019-08-02 RS RS20230591A patent/RS64381B1/sr unknown
- 2019-08-02 US US16/529,973 patent/US11471567B2/en active Active
- 2019-08-02 JP JP2021529544A patent/JP7208393B2/ja active Active
- 2019-08-02 CN CN201980062471.6A patent/CN112805364A/zh active Pending
- 2019-08-02 HU HUE19779967A patent/HUE062715T2/hu unknown
- 2019-08-02 AU AU2019315049A patent/AU2019315049B2/en active Active
- 2019-08-02 PL PL19779967.9T patent/PL3830243T3/pl unknown
- 2019-08-02 WO PCT/IB2019/056621 patent/WO2020026212A2/en active Application Filing
- 2019-08-02 HR HRP20230834TT patent/HRP20230834T1/hr unknown
- 2019-08-02 EP EP19779967.9A patent/EP3830243B1/en active Active
- 2019-08-02 FI FIEP19779967.9T patent/FI3830243T3/fi active
- 2019-08-02 KR KR1020217005498A patent/KR102530336B1/ko active IP Right Grant
- 2019-08-02 SG SG10202112210SA patent/SG10202112210SA/en unknown
- 2019-09-20 US US16/577,421 patent/US10980916B2/en active Active
-
2021
- 2021-02-09 ZA ZA2021/00888A patent/ZA202100888B/en unknown
-
2022
- 2022-10-17 US US17/967,250 patent/US20230093436A1/en active Pending
-
2023
- 2023-01-05 JP JP2023000388A patent/JP7303952B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kim et al. | Dynamic seeding and in vitro culture of hepatocytes in a flow perfusion system | |
| Risau | Angiogenic growth factors | |
| HRP20230834T1 (hr) | Postupci za proizvodnju personaliziranih krvnih žila | |
| Perets et al. | Enhancing the vascularization of three‐dimensional porous alginate scaffolds by incorporating controlled release basic fibroblast growth factor microspheres | |
| CN114350603B (zh) | 包含外泌体的间充质干细胞胞外基质及其制备和在细胞修复中的应用 | |
| EP0727481A2 (de) | Verfahren zur Kultivierung von Organfunktionszellen, dafür geeignete Trägerkörper und Vorrichtungen | |
| CN111973799A (zh) | 一种湿性抑菌水凝胶敷料及其制备方法 | |
| McIntosh et al. | Retinal capillary endothelial cells prefer different substrates for growth and migration | |
| CN105838675A (zh) | 一种造血干细胞无血清培养基 | |
| CN111514847A (zh) | 一种改性硅藻土的制备方法及其在含盐废水处理中的应用 | |
| DE10026482A1 (de) | Verfahren zur Herstellung eines bioartifiziellen Transplantats | |
| CN110404106A (zh) | 一种用于创伤修复的多糖敷料及其制备方法和应用 | |
| CN117731693A (zh) | 基于掺杂的多酶活性纳米材料在治疗炎症性疾病中的应用 | |
| RU2021101791A (ru) | Способы изготовления индивидуализированного кровеносного сосуда | |
| Unno et al. | Development of artificial placenta: oxygen metabolism of isolated goat fetuses with umbilical arteriovenous extracorporeal membrane oxygenation | |
| Kargi | Alkaloid formation by Catharanthus roseus cells in a packed column biofilm reactor | |
| JP6921737B2 (ja) | 軟骨組成物及びプロテオグリカン含量の修正方法 | |
| CN112957273A (zh) | 一种美容用干细胞因子培养方法 | |
| JPWO2020026212A5 (hr) | ||
| WO2022020446A1 (en) | A hybrid bioscaffold-intravascular catheter for cellular therapies | |
| CN112450205A (zh) | 一种间充质干细胞储存液 | |
| CN111454395A (zh) | 一种抗菌高分子及其制备方法 | |
| Petursson et al. | Effects of hypoxia on megakaryocytopoiesis and granulopoiesis | |
| RU2793910C1 (ru) | Способ стимуляции продукции нейротрофных ростовых факторов клетками нейроглии in vitro | |
| CN111378615A (zh) | 一种促进间充质干细胞成骨分化的培养基 |